CRM Lab NCBI Bibliography


  1. Lin B, Ziebro J, Smithberger E, Skinner KR, Zhao E, Cloughesy TF, Binder ZA, O’Rourke DM, Nathanson DA*, Furnari FB*, Miller CR*. EGFR, the Lazarus target for precision oncology in glioblastoma.  *Co-senior authors.  Neuro-oncology.  Sep 2022.  doi: 10.1093/neuonc/noac204.  PMID: 36125064
  2. Stackhouse CT, Anderson JC, Yue Z, Nguyen T, Eustace NJ, Ianov L, Langford CP, Wang J, Rowland JR, Xing C, Mikhail FM, Yang ES, Hjelmeland AB, Miller CR, Chen JY, Gillespie GY, Willey CD.  An in vivo model of glioblastoma radiation resistance identifies long non-coding RNAs and targetable kinases.  JCI Insight.  7(16):e148717 Aug 2022.  PMID: 35852875
  3. Rehman H, Chandrashekar DS, Balabhadrapatruni C, Nepal S, Balasubramanya SAH, Shelton AK, Skinner KR, Ma AH, Rao T, Agarwal S, Eich ML, Robinson AD, Naik G, Manne U, Netto GJ, Miller CR, Pan CX, Sonpavde G, Varambally S, Ferguson JE.  ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors.  JCI Insight.  7(16):e155899 Aug 2022.  PMID: 35852858
  4. Shonibare Z, Monavarian M, O’Connell K, Altomare D, Shelton A, Mehta S, Jaskula-Sztul R, Phaeton R, Starr MD, Whitaker R, Berchuck A, Nixon AB, Arend RC, Lee NY, Miller CR, Hempel N, Mythreye K.  Reciprocal Sox2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer.  Cell Reports.  40(4):111066 Jul 2022.  PMID: 35905726
  5. Tabury K, Monavarian M, Listik E, Shelton AK, Choi AS, Quintens R, Arend RC, Hempel N, Miller CR, Gyorrfy B, Mythreye K.  PVT1, a YAP1 dependent stress responsive lncRNA drives ovarian cancer metastasis and chemoresistance.  Life Science Alliance.  5(11): e202201370 Jul 2022. PMID: 35820706
  6. Krane GA, Shockley KR, Malarkey DE, Miller AD, Miller CR, Tokarz DA, Jensen HL, Janardhan KS, Breen M, Mariani CL.  Inter-pathologist agreement on diagnosis, classification and grading of canine glioma.  Veterinary and Comparative Oncology.  doi: 10.1111/vco.12853 Jul 2022.  PMID: 35856268
  7. McLendon RE, Yachnis AT, Miller CR, Ng HK.  CNS Tumor Classification: An Update on the Integration of Tumor Genetics.  Hematology/Oncology Clinics of North America.  36(1):1-21 Feb 2022.  PMID: 34763992
  8. Z, Monavarian M, O’Connell K, Altomare D, Shelton A, Mehta S, Jaskula-Sztul R, Phaeton R, Starr MD, Whitaker R, Berchuck A, Nixon AB, Arend R, Lee NY, Miller CR, Hempel N, Mythreye K.  Reciprocal epigenetic Sox2 regulation by SMAD1-SMAD3 is critical for anoikis resistance and metastasis in cancer.  bioRXiv.  January 12, 2022.  DOI: 10.1101/2022.01.11.475900
  9. Tabury K, Monavarian M, Listik E, Shelton AK, Choi AS, Quintens R, Arend R, Hempel N, Miller CR, Gyorrfy B, Mythreye K.  PVT1, a YAP1 dependent stress responsive lncRNA drives ovarian cancer metastasis and chemoresistance.  bioRXiv.  January 13, 2022.  DOI: 10.1101/2022.01.11.475893


  1. Krane GA, O’Dea CA, Malarkey DE, Miller AD, Miller CR, Tokarz DA, Jensen HL, Janardhan KS, Shockley KR, Flagler N, Rainess BA, Mariani CL.  Immunohistochemical evaluation of immune cell infiltration in canine gliomas.  Veterinary Pathology.  58(5):952-963 Sep 2021.  PMID: 34196247
  2. Almahariq MF, Quinn TJ, Kesarwani P, Kant S, Miller CR, Chinnaiyan P.  Inhibition of colony-stimulating factor-1 receptor enhances the efficacy of radiotherapy and reduces immune suppression in glioblastoma.  In Vivo.  35(1):119-129 Jan-Feb 2021. PMID: 33402457


  1. Amin SB, Anderson KJ, Boudreau CE, Martinez-Ledesma E, Kocakavuk E, Johnson KC, Barthel FP, Varn FS, Kassab C, Ling X, Kim H, Barter M, Ngan CY, Chapman M, Koehler JW, Miller AD, Miller CR, Porter BF, Rissi DR, Mazcko C, LeBlanc AK, Dickinson PJ, Packer RA, Taylor AR, Rossmeisl JH, Woolard KD, Heimberger AB, Levine JM, Verhaak RGW.  Comparative molecular life history of spontaneous canine and human gliomas.  Cancer Cell.  37(2):243-257 Feb 2020.  PMID: 32049048 PMCID: PMC7132629
  2. Buckley A, Hagler SB, Lettry V, Bago JR, Maingi SM, Khagi S, Ewend MG, Miller CR, Hingtgen SD.  Generation and profiling of tumor-homing induced neural stem cells from the skin of cancer patients.  Molecular Therapy.  28(7):1614-1627 Apr 2020.  PMID: 32402245  PMCID: PMC7132629
  3. Su YT, Butler M, Yu G, Zhang M, Zhang W, Hwang L, Tran AD, Bash RE, Schorzman AN, Zamboni WC, Wang X, Frye SV, Miller CR, Maric D, Terabe M, Gilbert MR, Earp HS, Wu J.  MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment.  Neuro-oncology Advances.  2(1):vdaa065 June 2020.  PMID: 32642716  PMCID: PMC7324055
  4. Gawley M, Almond L, Daniel S, Lastakchi S, Kaur S, Detta A, Cruickshank G, Miller R, Hingtgen S, Sheets K, McConville C.  Development and in vivo evaluation of irinotecan-loaded drug eluting seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme.  Journal of Controlled Release.  324:1-16 Aug 2020.  PMID: 32407745
  5. Skinner KR, Nabors LB, Miller CR.  Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics.  Neuro-oncology.  22(12):1713-1714 Dec 2020. PMID: 33257985  PMCID: PMC7746940 


  1. Schiff D, van den Bent M, Vogelbaum MA, Wick W, Miller CR, Taphoorn M, Pope W, Brown PD, Platten M, Jalali R, Armstrong T, Wen PY.  Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus.  Neuro-oncology.  21(7):837-853 Jul 2019.  PMID: 30757579  PMCID: PMC6620638
  2. Miller AD, Miller CR, Rossmeisl JH.  Canine primary intracranial cancer: A clinicopathologic and comparative review of glioma, meningioma, and choroid plexus tumors.  Frontiers in Oncology.  9:1151 Nov 2019.  PMID: 31788444  PMCID: PMC6856054


  1. Koehler JW*, Miller AD*, Miller CR*, Porter B*, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O’Sullivan MG, Rissi DR, Simpson RM, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK. A revised diagnostic classification of canine glioma: Towards validation of the canine glioma patient as a naturally occurring preclinical model for human glioma.  Journal of Neuropathology and Experimental Neurology.  77(11):1039-1054 Nov 2018.  PMID: 30239918  PMCID: PMC6181180  *Contributed equally
  2. Kesarwani P, Prabhu A, Kant S, Kumar P, Graham SF, Buelow K, Wilson G, Miller CR, Chinnaiyan P. Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma. Clinical Cancer Research.  24(15):3632-3643 Aug 2018.  PMID: 29691296
  3. Okolie O, Irvin DM, Bago JR, Sheets K, Satterlee A, Carey-Ewend AG, Lettry V, Dimitru R, Elton S, Ewend MG, Miller CR, Hingtgen SD.  Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection.  PLoS One.  13(7):e0198596 Jul 2018.  PMID: 29990322 PMCID: PMC6038981
  4. McNeill RSStroobant EESmithberger ECanoutas DAButler MKShelton AKPatel SD, Limas JC, Skinner KRBash RESchmid RSMiller CR.  PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.  PLoS One.  13(7):e0200014 Jul 2018.  PMID: 29975751  PMCID: PMC6033446
  5. Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY, Alliance for Clinical Trials in Oncology and Adult Brain Tumor Consortium (ABTC). Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: Results of Alliance N0874/ABTC 02.  Neuro-oncology.  20(4):546-556 Mar 2018.  PMID: 29016887  PMCID:  PMC5909661
  6. Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Chan TA, Riggins GJ, Sulman EP, Lang F, Creighton CJ, Deneen B, Miller CR, Picketts DJ, Kannan K, Huse JT. Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.  Nature Communications.  9(1):1057 Mar 2018.  PMID: 29535300  PMCID:  PMC5849741
  7. Graham-Gurysh EG, Moore KM, Satterlee AB, Sheets KT, Lin FC, Bachelder EM, Miller CR, Hingtgen S, Ainslie KM. Sustained delivery of doxorubicin via acetalated dextran scaffold prevents glioblastoma recurrence after surgical resection.  Molecular Pharmaceutics.  15(3):1309-1318 Mar  PMID: 29342360  PMCID:  PMC5999333
  8. Connolly NP, Shetty AC, Stokum JA, Hoeschele I, Siegel MBMiller CR, Kim AJ, Ho CY, Davila E, Simard JM, Devine SE, Rossmeisl JH, Holland EC, Winkles JA, Woodworth GF. Cross-species transcriptional analysis reveals conserved and host-specific neoplastic processes in mammalian glioma.  Scientific Reports.  8(1):1180 Jan 2018.  PMID: 29352201  PMCID: PMC5775420
  9. Wu JFrady LNBash RE, Cohen SM, Schorzman AN, Su YT, Irvin DM, Zamboni WC, Wang X, Frye SV, Ewend MG, Sulman EP, Gilbert MR, Earp HS, Miller CR. MerTK as a therapeutic target in glioblastoma.  Neuro-oncology. 20(1):92-102 Jan 2018.  PMID: 28605477  PMCID:  PMC5761530


  1. Khagi S, Miller CR. Putting “multiforme” back into glioblastoma: intratumoral transcriptome heterogeneity is a consequence of its complex morphology.  Neuro-oncology.  Neuro-oncology.  19(12):1570-1571 Nov 2017.  PMID: 29016836  PMCID: PMC5716077
  2. McNeill RSCanoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DMBash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.  Neuro-oncology.  19(11):1469-1480 Oct 2017.  PMID: 28379424  PMCID:  PMC5737415
  3. Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, Johnson GL, Anders CK. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.  Neuro-oncology.  19(11):1481-1493 Oct 2017.  PMID: 28486691  PMCID:  PMC5737524
  4. Vitucci M*, Irvin DM*, McNeill RSSchmid RS, Simon JM, Dhruv HD, Siegel MB, Werneke AMBash RE, Kim S, Berens ME, Miller CR.  Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.  Neuro-oncology.  19(9):1237-1257 Sep 2017.  *Co-first authors. PMID: 28398584 PMCID:  PMC5570221
  5. Bago JR, Okolie O, Dumitru R, Ewend MG, Parker JS, Vander Werff R, Underhill TM, Schmid RSMiller CR, Hingtgen SD. Tumor-homing cytotoxic human induced neural stem cells for cancer therapy. Science Translational Medicine. 9(375):eaah6510 Feb 2017. PMID: 28148846
  6. Irvin DMMcNeill RSBash REMiller CR. Intrinsic astrocyte heterogeneity influences tumor growth in glioma mouse models. Brain Pathology. 27(1):36-50 Jan 2017. PMID: 26762242  PMCID:  PMC5322824


  1. Okolie O, Bago JR, Schmid RSIrvin DMBash RE, Miller CR*, Hingtgen SD*.  Reactive astrocytes potentiate tumor aggressiveness in murine glioma resection and recurrence model.  Neuro-oncology.  18(12):1622-1633 Dec 2016.  *Co-senior authors  PMID: 27298311  PMCID: PMC5791515
  2. McNeill RSIrvin DMMiller CR.  BRAF mutations open doors to ENU-induced gliomagenesis.  American Journal of Pathology.  186(10):2551-2554 Oct 2016.  PMID: 27543966  PMCID: PMC5222976
  3. LeBlanc AK, Mazcko C, Brown DB, Koehler JW, Miller AD, Miller CR, Bentley RT, Packer RA, Breen M, Boudreau B, Levine JM, Simpson MR, Halsey C, Kisseberth W, Rossmeisl JH, Dickinson PJ, Fan T, Corps K, Aldape K, Puduvalli V, Gilbert MR.  Creation of an NCI Comparative Brain Tumor Consortium: Informing the translation of new knowledge from canine to human brain tumor patients.  Neuro-oncology.  18(9):1209-1218 Sep 2016.  PMID: 27179361  PMCID: PMC4999002
  4. Schmid RS, Simon JM, Vitucci MMcNeill RSBash REWerneke AMHuey LWhite KK, Ewend MG, Wu JMiller CR.  Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation, but resistant to temozolomide.  Neuro-oncology.  18(7):962-973 Jul 2016.  PMID: 26826202  PMCID: PMC4896545
  5. Bago JR, Alfonso-Pecchio A, Okolie O, Dumitru R, Rinkenbaugh A, Baldwin AS, Miller CR, Magness ST, Hingtgen SD.  Therapeutically engineered induced neural stem cells are tumor-homing and inhibit progression of glioblastoma.  Nature Communications.  7:10593 Feb 2016.  PMID: 26830441 PMCID: PMC4740908
  6. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao A, Grifford M, Cherniack AD, Zhang H, Poisson L, Rao A, Mikkelsen T, Lau CC, Yung WKA, Rabadan R, Huse J, Brat DJ, Lehman N, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, Cancer Genome Atlas Research Network, Noushmehr H, Iavarone A, Verhaak RGW.  Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma.  Cell.  164(3):550-563 Jan 2016. PMID: 26824661 PMCID:  PMC4754110


  1. Prabhu A, Sarcar B, Miller CR, Kim SH, Nakano I, Forsyth P, Chinnaiyan P.  Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis.  Neuro-oncology.  17(9):1220-1230 Sep 2015.  PMID: 25712957  PMCID: PMC4588752
  2. Cancer Genome Atlas Research Network.  Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas.  New England Journal of Medicine.  372(26):2481-2498.  Jun 2015.  PMID: 26061751  PMCID: PMC4530011
  3. McNeill RSVitucci MWu JMiller CR.  Contemporary murine models in preclinical astrocytoma drug development.  Neuro-oncology.  17(1):12-28 Jan 2015.  PMID: 25246428  PMCID: PMC4483055


  1. Galvao RP, Kasina A, McNeill RS, Harbin JE, Foreman O, Verhaak RGW, Nishiyama A, Miller CR, Zong H.  Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multi-step reactivation process.  Proceedings of the National Academy of Science USA.  111(40):E4214-E4223 Oct 2014.  PMID: 25246577  PMCID: PMC4210043
  2. McNeill RSSchmid RSBash REVitucci MWhite KKWerneke AMConstance BHHuff BMiller CR.  Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.  Journal of Visualized Experiments.  90:e51763 Aug 2014.  PMID: 25146643
  3. Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, Yip S, Yen K, Costello JF, Chang S.  Where are we now?  And where are we going?  A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma workshop.  Neuro-oncology.  16(2):173-178 Jan 2014.  PMID: 24305708  PMCID: PMC3895389


  1. Song Y, Zhang Q, Kutlu B, Difilippantonio S, Bash R, Gilbert D, Yin C, O’Sullivan TN, Yang C, Kozlov S, Bullitt E, McCarthy KD, Kafri T, Louis DN, Miller CR, Hood L, Van Dyke T.  Evolutionary etiology of high-grade astrocytomas.  Proceedings of the National Academy of Science USA.  110(44):17933-17938 Oct 2013.  PMID: 24114272 PMCID: PMC3816471
  2. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro, Friedman W, Andrews DW, Guha A, Iacocca M, O’Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, and Cancer Genome Atlas Research Network.  The somatic genomic landscape of glioblastoma.  Cell.  155(2):462-477 Oct 2013.  PMID: 24120142  PMCID: PMC3910500
  3. Vitucci M*, Karpinich NO*, Bash REWerneke AMSchmid RSWhite KKMcNeill RSHuff B, Wang S, Van Dyke T, Miller CR.  Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.  *Co-first authors.  Neuro-oncology.  15(10):1317-1329 Oct 2013.  PMID: 23814263  PMCID: PMC3779038


  1. Schmid RSVitucci MMiller CR.  Genetically engineered mouse models of diffuse gliomas.  Brain Research Bulletin.  88(1):72-79 May 2012.  PMID: 21684324


  1. Vitucci M, Hayes DN, Miller CR.  Gene expression profiling of gliomas:  Merging genomic and histopathological classification for personalised therapy.  British Journal of Cancer.  104(4):545-553 Feb 2011.  PMID: 21119666  PMCID: PMC3049580


  1. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN and Cancer Genome Atlas Research Network.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.  Cancer Cell.  17(1):98-110 Jan 2010.  PMID: 20129251  PMCID: PMC2818769


  1. Miller CR, Karpinich NO, Zhang Q, Bullitt E, Kozlov S, and Van Dyke T.  Modeling astrocytomas in a family of inducible genetically engineered mice: implications for preclinical cancer drug development.  In: Van Meir EG (ed), CNS Cancer, Models, Prognostic Factors, and Targets, 1st Ed., Cambridge: Springer, 2009.  Chapter 7: Pages 119-145.  ISBN 978-1-60327-552-1.
UAB the University of Alabama at Birmingham home
UAB is an Equal Opportunity/Affirmative Action Employer committed to fostering a diverse, equitable and family-friendly environment in which all faculty and staff can excel and achieve work/life balance irrespective of race, national origin, age, genetic or family medical history, gender, faith, gender identity and expression as well as sexual orientation. UAB also encourages applications from individuals with disabilities and veterans.